Volume 145, Issue 4, Pages e3 (October 2013)

Slides:

Advertisements

Similar presentations

Volume 62, Issue 2, Pages (February 2015)

Advertisements

Volume 149, Issue 6, Pages (November 2015)

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Volume 148, Issue 2, Pages e1 (February 2015)

Volume 146, Issue 2, Pages e6 (February 2014)

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Pancreatic Fusion Abnormality Found During a Whipple Procedure

Volume 139, Issue 4, Pages (October 2010)

Volume 148, Issue 1, Pages e1 (January 2015)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Volume 131, Issue 2, Pages (August 2006)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers Thilo Rattay, Ian P. Dumont, Hauke.

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Volume 139, Issue 4, Pages (October 2010)

Volume 153, Issue 4, Pages (October 2017)

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 143, Issue 3, Pages e5 (September 2012)

Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Volume 149, Issue 4, Pages e1 (October 2015)

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Pancreatic Fusion Abnormality Found During a Whipple Procedure

Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz,

Volume 142, Issue 4, Pages (April 2012)

Volume 146, Issue 2, Pages (February 2014)

Volume 152, Issue 6, Pages e2 (May 2017)

Volume 138, Issue 2, Pages e1 (February 2010)

Michael Biermer, Thomas Berg Gastroenterology

Volume 140, Issue 2, Pages e1 (February 2011)

Volume 154, Issue 4, Pages (March 2018)

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Volume 139, Issue 4, Pages e3 (October 2010)

Volume 136, Issue 2, Pages e3 (February 2009)

Volume 141, Issue 5, Pages (November 2011)

Volume 146, Issue 2, Pages e6 (February 2014)

Volume 146, Issue 7, Pages e3 (June 2014)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 138, Issue 1, Pages (January 2010)

A. Sidney Barritt, Michael W. Fried Gastroenterology

Volume 130, Issue 4, Pages (April 2006)

Volume 145, Issue 5, Pages e5 (November 2013)

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Impact of New Hepatitis C Treatments in Different Regions of the World

Volume 142, Issue 6, Pages (May 2012)

Volume 139, Issue 4, Pages e4 (October 2010)

Volume 151, Issue 5, Pages e1 (November 2016)

Volume 138, Issue 1, Pages e2 (January 2010)

Volume 144, Issue 7, Pages e2 (June 2013)

Rafael Esteban, Maria Buti Gastroenterology

Genetic Factors and Hepatitis C Virus Infection

Volume 148, Issue 2, Pages e1 (February 2015)

Jeremy P. Dwyer, Patrick Hosking, John Lubel Gastroenterology

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Volume 143, Issue 3, Pages e5 (September 2012)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

This Month in Gastroenterology

Volume 147, Issue 2, Pages e1 (August 2014)

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Volume 130, Issue 7, Pages (June 2006)

Volume 139, Issue 5, Pages (November 2010)

Volume 147, Issue 6, Pages (December 2014)

Volume 135, Issue 2, Pages (August 2008)

Controversies in Liver Transplantation for Hepatitis C

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Volume 148, Issue 1, Pages (January 2015)

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Presentation transcript:

Volume 145, Issue 4, Pages 790-800.e3 (October 2013) Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection Patrick Marcellin, Curtis Cooper, Luis Balart, Dominique Larrey, Terry Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman, Emily Labriola–Tompkins, Sophie Le Pogam, Isabel Nájera, Denise Thomas, Gregory Hooper, Nancy S. Shulman, Ying Zhang, Mercidita T. Navarro, Chin Yin Lim, Michael Brunda, Norah A. Terrault, Ellen S. Yetzer Gastroenterology Volume 145, Issue 4, Pages 790-800.e3 (October 2013) DOI: 10.1053/j.gastro.2013.06.051 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 ATLAS study design. Gastroenterology 2013 145, 790-800.e3DOI: (10.1053/j.gastro.2013.06.051) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Patient disposition, including reasons for premature withdrawal from treatment. Gastroenterology 2013 145, 790-800.e3DOI: (10.1053/j.gastro.2013.06.051) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 Virologic response rates, sustained virologic response (SVR) and relapse rates (modified intention-to-treat analysis). Gastroenterology 2013 145, 790-800.e3DOI: (10.1053/j.gastro.2013.06.051) Copyright © 2013 AGA Institute Terms and Conditions

Figure 4 Sustained virologic response (SVR) rates (A) by IL28B genotype (CC vs non-CC). Does not include 55 patients with unknown/undetermined IL28B genotypes. (B) by HCV subgenotype (1a vs 1b). Does not include 3 patients with unknown/other HCV subgenotypes. Gastroenterology 2013 145, 790-800.e3DOI: (10.1053/j.gastro.2013.06.051) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 1 Mean HCV RNA levels during 24 weeks of treatment Gastroenterology 2013 145, 790-800.e3DOI: (10.1053/j.gastro.2013.06.051) Copyright © 2013 AGA Institute Terms and Conditions